Correlation Between Ocuphire Pharma and Apellis Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Ocuphire Pharma and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ocuphire Pharma and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ocuphire Pharma and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Ocuphire Pharma and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ocuphire Pharma with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ocuphire Pharma and Apellis Pharmaceuticals.
Diversification Opportunities for Ocuphire Pharma and Apellis Pharmaceuticals
0.82 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Ocuphire and Apellis is 0.82. Overlapping area represents the amount of risk that can be diversified away by holding Ocuphire Pharma and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Ocuphire Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ocuphire Pharma are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Ocuphire Pharma i.e., Ocuphire Pharma and Apellis Pharmaceuticals go up and down completely randomly.
Pair Corralation between Ocuphire Pharma and Apellis Pharmaceuticals
Given the investment horizon of 90 days Ocuphire Pharma is expected to under-perform the Apellis Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Ocuphire Pharma is 1.03 times less risky than Apellis Pharmaceuticals. The stock trades about -0.03 of its potential returns per unit of risk. The Apellis Pharmaceuticals is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest 5,286 in Apellis Pharmaceuticals on September 1, 2024 and sell it today you would lose (1,893) from holding Apellis Pharmaceuticals or give up 35.81% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 94.73% |
| Values | Daily Returns |
Ocuphire Pharma vs. Apellis Pharmaceuticals
Performance |
| Timeline |
| Ocuphire Pharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Apellis Pharmaceuticals |
Ocuphire Pharma and Apellis Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Ocuphire Pharma and Apellis Pharmaceuticals
The main advantage of trading using opposite Ocuphire Pharma and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ocuphire Pharma position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.| Ocuphire Pharma vs. Reviva Pharmaceuticals Holdings | Ocuphire Pharma vs. Protalix Biotherapeutics | Ocuphire Pharma vs. Eyepoint Pharmaceuticals | Ocuphire Pharma vs. Sellas Life Sciences |
| Apellis Pharmaceuticals vs. Tff Pharmaceuticals | Apellis Pharmaceuticals vs. Eliem Therapeutics | Apellis Pharmaceuticals vs. Inhibrx | Apellis Pharmaceuticals vs. Enliven Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |